Gujarat Kidney And Super Speciality Limited IPO Fund Utilisation Report Q3 FY26
Gujarat Kidney And Super Speciality Limited's IPO fund utilisation report for Q3 FY26 shows ₹250.80 Crore raised. As of December 31, 2025, ₹193.05 Crore remains unutilised across various objectives including hospital acquisitions and capex. ₹50.04 Crore was used for general corporate purposes.
This is a routine regulatory filing and does not contain any new financial performance data or significant corporate actions that would materially impact the company's stock or operations.
The report is a routine monitoring agency submission detailing the utilisation of IPO funds. It confirms adherence to the offer document's disclosures, indicating no significant negative or positive deviations at this stage.
Gujarat Kidney And Super Speciality Limited has submitted its Monitoring Agency Report for the quarter ended December 31, 2025, detailing the utilisation of funds raised through its Initial Public Offer (IPO). The report, issued by Brickwork Ratings India Private Limited, confirms that the utilisation of IPO proceeds is in line with the disclosures made in the Offer Document.
The company raised ₹250.80 Crore through the Fresh Issue of Equity Shares. For the quarter ended December 31, 2025, the total unutilised amount was ₹193.05 Crore. Significant unutilised amounts remain for the acquisition of Parekhs Hospital (₹77.00 Crore), part-payment for "Ashwini Medical Centre" (₹12.40 Crore), acquisition of shares in subsidiary "Harmony Medicare Private Limited" (₹10.78 Crore), funding capital expenditure for a new hospital in Vadodara (₹30.10 Crore), purchasing robotics equipment (₹6.83 Crore), and funding inorganic growth and general corporate purposes (₹37.40 Crore).
Funds utilised for General Corporate Purposes (GCP) during the quarter amounted to ₹50.04 Crore, covering advance payments for land purchase, commission, and OD repayment. The report also indicates that the implementation of objects is generally ongoing, with projected completion dates extending up to the Financial Year 2026-27 for most objectives, including acquisitions and capital expenditure.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.